^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SCRI-CAR19x22v2
i
Other names: SCRI-CAR19x22v2, Patient-derived CD19- and CD22 specific CAR
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Seattle Children's Hospital
Drug class:
CD19-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
Related drugs:
1year
PLAT-05: A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia (clinicaltrials.gov)
P1, N=78, Active, not recruiting, Seattle Children's Hospital | Recruiting --> Active, not recruiting
Enrollment closed • CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
SCRI-CAR19x22v2
over1year
PLAT-05: A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia (clinicaltrials.gov)
P1, N=80, Recruiting, Seattle Children's Hospital | Trial primary completion date: Jun 2023 --> Sep 2023
Trial primary completion date • CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
SCRI-CAR19x22v2
over1year
PLAT-05: A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia (clinicaltrials.gov)
P1, N=80, Recruiting, Seattle Children's Hospital | Trial primary completion date: Dec 2022 --> Jun 2023
Trial primary completion date • CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
SCRI-CAR19x22v2
almost3years
PLAT-05: A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia (clinicaltrials.gov)
P1, N=80, Recruiting, Seattle Children's Hospital | N=60 --> 80 | Trial completion date: Nov 2034 --> Mar 2035 | Trial primary completion date: Mar 2022 --> Dec 2022
Enrollment change • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
SCRI-CAR19x22v2
Share via
